These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
392 related articles for article (PubMed ID: 23200321)
1. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Young NR; Liu J; Pierce C; Wei TF; Grushko T; Olopade OI; Liu W; Shen C; Seiwert TY; Cohen EE Mol Oncol; 2013 Jun; 7(3):359-68. PubMed ID: 23200321 [TBL] [Abstract][Full Text] [Related]
2. Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. Rogers SJ; Box C; Chambers P; Barbachano Y; Nutting CM; Rhŷs-Evans P; Workman P; Harrington KJ; Eccles SA J Pathol; 2009 May; 218(1):122-30. PubMed ID: 19197951 [TBL] [Abstract][Full Text] [Related]
3. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab. Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260 [TBL] [Abstract][Full Text] [Related]
4. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Pernas FG; Allen CT; Winters ME; Yan B; Friedman J; Dabir B; Saigal K; Mundinger GS; Xu X; Morris JC; Calvo KR; Van Waes C; Chen Z Clin Cancer Res; 2009 Apr; 15(7):2361-72. PubMed ID: 19318490 [TBL] [Abstract][Full Text] [Related]
5. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells. Jameson MJ; Beckler AD; Taniguchi LE; Allak A; Vanwagner LB; Lee NG; Thomsen WC; Hubbard MA; Thomas CY Mol Cancer Ther; 2011 Nov; 10(11):2124-34. PubMed ID: 21878657 [TBL] [Abstract][Full Text] [Related]
6. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711 [TBL] [Abstract][Full Text] [Related]
7. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718 [TBL] [Abstract][Full Text] [Related]
8. Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma. Hoeben A; Martin D; Clement PM; Cools J; Gutkind JS Int J Cancer; 2013 Mar; 132(5):1042-50. PubMed ID: 22865653 [TBL] [Abstract][Full Text] [Related]
9. Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma. Baba Y; Maeda T; Suzuki A; Takada S; Fujii M; Kato Y Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134774 [TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133 [TBL] [Abstract][Full Text] [Related]
11. Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway. Maseki S; Ijichi K; Tanaka H; Fujii M; Hasegawa Y; Ogawa T; Murakami S; Kondo E; Nakanishi H Br J Cancer; 2012 Mar; 106(6):1196-204. PubMed ID: 22315058 [TBL] [Abstract][Full Text] [Related]
12. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells. Yu Y; Xiao Z; Lei C; Ma C; Ding L; Tang Q; He Y; Chen Y; Chang X; Zhu Y; Zhang H BMC Cancer; 2023 Aug; 23(1):732. PubMed ID: 37553597 [TBL] [Abstract][Full Text] [Related]
13. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074 [TBL] [Abstract][Full Text] [Related]
14. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342 [TBL] [Abstract][Full Text] [Related]
15. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. Wang Z; Martin D; Molinolo AA; Patel V; Iglesias-Bartolome R; Degese MS; Vitale-Cross L; Chen Q; Gutkind JS J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25099740 [TBL] [Abstract][Full Text] [Related]
16. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581 [TBL] [Abstract][Full Text] [Related]
17. Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib. Taguchi T; Tsukuda M; Imagawa-Ishiguro Y; Kato Y; Sano D Oncol Rep; 2008 Jan; 19(1):65-71. PubMed ID: 18097577 [TBL] [Abstract][Full Text] [Related]
18. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177 [TBL] [Abstract][Full Text] [Related]
19. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102 [TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]